| 引用本文：孔繁翠.创新药价值评估的国际经验比较及启示[J].中国卫生政策研究,2022,15(6):17-23 |
|
| 创新药价值评估的国际经验比较及启示 |
| 投稿时间：2022-05-06 修订日期：2022-06-06 PDF全文浏览 HTML全文浏览 |
| 孔繁翠 |
| 中国人民大学公共管理学院 北京 100872 |
| 摘要:随着我国医药卫生体制改革的不断深入，以价值为导向的创新药医保谈判准入模式已经逐步确立，如何科学开展创新药的价值评估已成为政府决策部门和社会各界关注的重要问题。本文对英国、德国、法国、加拿大四个国家的创新药价值评估体系与评估流程进行了系统梳理与对比，总结了英国关于药物经济学评价以及德国、法国、加拿大关于附加临床收益评估的过往经验；在此基础上，针对我国的创新药价值评估流程，在构建创新药附加临床收益评估体系、完善创新药医保准入的谈判规则、完善创新药医保准入的决策依据三个方面提出了相关建议。 |
| 关键词:创新药 价值评估 医保准入 药物经济学 临床收益 |
|
| Comparison of international experience and enlightenment in the value assessment of innovative drugs |
| KONG Fan-cui |
| School of Public Administration, Renmin University of China, Beijing 100872, China |
| Abstract:With the advancement of medicine and healthcare system reform in China, a value-oriented mode of negotiation for permit to medical insurance has been established for innovative drugs. Therefore, how to appropriately conduct the value assessment of innovative drugs has become an important issue concerning decision-making government departments and all sectors of society. In this study, we systematically reviewed and compared the value assessment system and process for innovative drugs in the UK, Germany, France, and Canada. We summarized the experience of the UK in pharmacoeconomic evaluation and of Germany, France, and Canada in the evaluation of additional clinical benefit. Based on these results, this paper provided constructive ideas and suggestions for China’s value assessment process of innovative drugs in the following three aspects: development of an additional clinical benefit evaluation system for innovative drugs; optimization of the negotiation policy for innovative drugs’ access to the medical insurance; and optimization of the decision-making reference for innovative drugs’ access to the medical insurance. |
| Key words:Innovative drugs Value assessment Permit to medical insurance Pharmacoeconomics Clinical benefits |
| 摘要点击次数: 421 全文下载次数: 204 |
|
|
